Blog

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news Meet us at AACR-NCI-EORTC! Physiomics is attending the AACR-NCI-EORTC International Conference on Molecular Targets And Cancer Therapeutics at the Hynes Convention Center, Boston on...

Read More

Pete joins us with experience working for a wide variety of life sciences businesses across R&D and commercial operations, read on to find out why he is excited to join Physiomics and where he sees the most potential!   Q: What attracted you to the role at Physiomics? A: “Having worked across the biopharma industry for many years, I’m acutely aware of the mounting pressures drug development companies...

Read More

Leading mathematical modelling company, supporting oncology drug development. From us to you - curated cutting-edge research and insights. Welcome to our newsletter, where we share the latest updates from Physiomics and offer insights on the pivotal news shaping the dynamic world of drug development.   Top news   Exciting new contract with Numab! We are pleased to announce that we have been awarded a further contract by existing client, Numab Therapeutics. The project...

Read More

Cancer therapies are often associated with a ‘Goldilocks Window’ of optimal dosing: striking a balance where efficacy is maximised and toxicity is minimised. While mathematical modelling offers a powerful tool to inform optimal treatment approaches in cancer drug development, determining the right level of mechanistic detail to include in a model also requires careful consideration – hitting the right balance is both art and science.   You...

Read More

Written by David Orrell As the physicist Richard Feynman famously observed in 1982: “Nature isn’t classical, dammit, and if you want to make a simulation of nature, you’d better make it quantum mechanical.” And as he went on, “by golly it’s a wonderful problem, because it doesn’t look so easy.” Indeed, the configuration of something like a drug compound, and its interaction with other substances, is ultimately...

Read More

Recently, combination treatments involving immunotherapy have emerged as an exciting new way to tackle cancer [1].The spotlight has fallen especially on immune checkpoint inhibitors. In this post, we discuss how modelling can be used to unlock key insights to help optimise the promise of combination therapies.  Immunotherapy as a treatment approach has revolutionised oncology – and is one of our key areas of focus here...

Read More

Written by Dr Jim Millen In these unprecedented times the life sciences sector is rightly focused on finding a vaccine against COVID-19.  It is estimated that it will take 12 to 18 months before an effective vaccine can be developed and manufactured.  In the meantime, health providers are focusing on managing the immediate crisis by delaying treatment of other less-urgent and non-coronavirus cases. But what challenges...

Read More

Written by David Orrell In a 1904 paper on weather forecasting, the Norwegian physicist and meteorologist Vilhelm Bjerknes noted that the accuracy of a predictive model depends on two things: “1. A sufficiently accurate knowledge of the state of the atmosphere at the initial time. 2. A sufficiently accurate knowledge of the laws according to which one state of the atmosphere develops from another.” Or in...

Read More

Written by David Orrell As discussed in the last post, models have two functions – to describe, and to predict. In systems biology, and other areas of science, these are often conflated. We say a model is predictive, when really we mean it is descriptive. But prediction – from the Latin praedicere for “make known beforehand” – is not the same as just reproducing something that...

Read More

Written by David Orrell.    The Virtual Tumour (“VT”) is the main program we use at Physiomics to optimise oncology treatments and predict the effects of drug combinations. This post is the first in a series that will describe the aims, motivations, and some of the history of the project – and gives a peek at the mathematics inside. Today’s topic: why we built the model. The VT,...

Read More